Spasmophilia  ||| S:0 E:13 ||| JJ
comorbidity  ||| S:13 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
fibromyalgia  ||| S:28 E:41 ||| JJ
syndrome  ||| S:41 E:50 ||| NN
To  ||| S:50 E:53 ||| TO
evaluate  ||| S:53 E:62 ||| VB
the  ||| S:62 E:66 ||| DT
role  ||| S:66 E:71 ||| NN
of  ||| S:71 E:74 ||| IN
spasmophilia  ||| S:74 E:87 ||| NNS
( ||| S:87 E:88 ||| -LRB-
SP ||| S:88 E:90 ||| NNP
)  ||| S:90 E:92 ||| -RRB-
in  ||| S:92 E:95 ||| IN
fibromyalgia  ||| S:95 E:108 ||| JJ
syndrome  ||| S:108 E:117 ||| NN
( ||| S:117 E:118 ||| -LRB-
FM ||| S:118 E:120 ||| NNP
) ||| S:120 E:121 ||| -RRB-
.  ||| S:121 E:123 ||| .
Three  ||| S:123 E:129 ||| CD
hundred  ||| S:129 E:137 ||| CD
and  ||| S:137 E:141 ||| CC
fourteen  ||| S:141 E:150 ||| JJ
patients  ||| S:150 E:159 ||| NNS
( ||| S:159 E:160 ||| -LRB-
280  ||| S:160 E:164 ||| CD
F ||| S:164 E:165 ||| NN
,  ||| S:165 E:167 ||| ,
34  ||| S:167 E:170 ||| CD
M ||| S:170 E:171 ||| NNP
)  ||| S:171 E:173 ||| -RRB-
with  ||| S:173 E:178 ||| IN
a  ||| S:178 E:180 ||| DT
diagnosis  ||| S:180 E:190 ||| NN
of  ||| S:190 E:193 ||| IN
FM  ||| S:193 E:196 ||| NNP
or  ||| S:196 E:199 ||| CC
FM  ||| S:199 E:202 ||| NNP
and  ||| S:202 E:206 ||| CC
spasmophilia  ||| S:206 E:219 ||| NNS
( ||| S:219 E:220 ||| -LRB-
FM+SP ||| S:220 E:225 ||| NNP
)  ||| S:225 E:227 ||| -RRB-
were  ||| S:227 E:232 ||| VBD
recruited ||| S:232 E:241 ||| VBN
.  ||| S:241 E:243 ||| .
Clinical  ||| S:243 E:252 ||| JJ
assessment  ||| S:252 E:263 ||| NN
of  ||| S:263 E:266 ||| IN
patients  ||| S:266 E:275 ||| NNS
and  ||| S:275 E:279 ||| CC
controls  ||| S:279 E:288 ||| NNS
included  ||| S:288 E:297 ||| VBD
the  ||| S:297 E:301 ||| DT
Questionnaires  ||| S:301 E:316 ||| NNP
FIQ ||| S:316 E:319 ||| NNP
,  ||| S:319 E:321 ||| ,
HAQ  ||| S:321 E:325 ||| NNP
and  ||| S:325 E:329 ||| CC
the  ||| S:329 E:333 ||| DT
tender  ||| S:333 E:340 ||| NN
point  ||| S:340 E:346 ||| NN
( ||| S:346 E:347 ||| -LRB-
TP ||| S:347 E:349 ||| NNP
)  ||| S:349 E:351 ||| -RRB-
count ||| S:351 E:356 ||| NN
.  ||| S:356 E:358 ||| .
Life-time  ||| S:358 E:368 ||| NNP
or  ||| S:368 E:371 ||| CC
ongoing  ||| S:371 E:379 ||| JJ
psychiatric  ||| S:379 E:391 ||| JJ
aspects  ||| S:391 E:399 ||| NNS
were  ||| S:399 E:404 ||| VBD
evaluated  ||| S:404 E:414 ||| VBN
by  ||| S:414 E:417 ||| IN
trained  ||| S:417 E:425 ||| JJ
psychiatrists  ||| S:425 E:439 ||| NN
by  ||| S:439 E:442 ||| IN
means  ||| S:442 E:448 ||| NNS
of  ||| S:448 E:451 ||| IN
the  ||| S:451 E:455 ||| DT
classic  ||| S:455 E:463 ||| JJ
scales ||| S:463 E:469 ||| NNS
:  ||| S:469 E:471 ||| :
Structured  ||| S:471 E:482 ||| NNP
Clinical  ||| S:482 E:491 ||| NNP
Interview  ||| S:491 E:501 ||| NNP
( ||| S:501 E:502 ||| -LRB-
SCID ||| S:502 E:506 ||| NNP
)  ||| S:506 E:508 ||| -RRB-
for  ||| S:508 E:512 ||| IN
DSM-IV ||| S:512 E:518 ||| JJ
.  ||| S:518 E:520 ||| .
The  ||| S:520 E:524 ||| DT
following  ||| S:524 E:534 ||| JJ
analysis  ||| S:534 E:543 ||| NN
were  ||| S:543 E:548 ||| VBD
evaluated ||| S:548 E:557 ||| VBN
:  ||| S:557 E:559 ||| :
cytokine  ||| S:559 E:568 ||| CD
( ||| S:568 E:569 ||| -LRB-
IL1 ||| S:569 E:572 ||| NNP
,  ||| S:572 E:574 ||| ,
IL2 ||| S:574 E:577 ||| NNP
,  ||| S:577 E:579 ||| ,
IL6 ||| S:579 E:582 ||| NNP
,  ||| S:582 E:584 ||| ,
IL8 ||| S:584 E:587 ||| NNP
,  ||| S:587 E:589 ||| ,
IL10 ||| S:589 E:593 ||| CD
) ||| S:593 E:594 ||| -RRB-
,  ||| S:594 E:596 ||| ,
TNF-α ||| S:596 E:601 ||| NNP
,  ||| S:601 E:603 ||| ,
cortisol ||| S:603 E:611 ||| NN
,  ||| S:611 E:613 ||| ,
GH ||| S:613 E:615 ||| NNP
,  ||| S:615 E:617 ||| ,
ACTH ||| S:617 E:621 ||| NNP
,  ||| S:621 E:623 ||| ,
IGF1 ||| S:623 E:627 ||| NNP
,  ||| S:627 E:629 ||| ,
5HT ||| S:629 E:632 ||| NNP
,  ||| S:632 E:634 ||| ,
intracellular  ||| S:634 E:648 ||| VBG
Mg ||| S:648 E:650 ||| NNP
,  ||| S:650 E:652 ||| ,
plasma  ||| S:652 E:659 ||| FW
calcium  ||| S:659 E:667 ||| FW
p ||| S:667 E:668 ||| FW
( ||| S:668 E:669 ||| -LRB-
Ca ||| S:669 E:671 ||| NNP
) ||| S:671 E:672 ||| -RRB-
,  ||| S:672 E:674 ||| ,
PTH ||| S:674 E:677 ||| NNP
,  ||| S:677 E:679 ||| ,
( ||| S:679 E:680 ||| -LRB-
25 ||| S:680 E:682 ||| CD
( ||| S:682 E:683 ||| -LRB-
OH ||| S:683 E:685 ||| NNP
) ||| S:685 E:686 ||| -RRB-
D ||| S:686 E:687 ||| NNP
)  ||| S:687 E:689 ||| -RRB-
and  ||| S:689 E:693 ||| CC
thyroid  ||| S:693 E:701 ||| JJ
functionality ||| S:701 E:714 ||| NN
.  ||| S:714 E:716 ||| .
Some  ||| S:716 E:721 ||| DT
typical  ||| S:721 E:729 ||| JJ
symptoms  ||| S:729 E:738 ||| NNS
were  ||| S:738 E:743 ||| VBD
investigated ||| S:743 E:755 ||| VBN
.  ||| S:755 E:757 ||| .
Eighty-one  ||| S:757 E:768 ||| JJ
patients  ||| S:768 E:777 ||| NNS
resulted  ||| S:777 E:786 ||| VBD
positive  ||| S:786 E:795 ||| JJ
for  ||| S:795 E:799 ||| IN
spamophilia  ||| S:799 E:811 ||| NNS
( ||| S:811 E:812 ||| -LRB-
FM+SP ||| S:812 E:817 ||| NNP
) ||| S:817 E:818 ||| -RRB-
,  ||| S:818 E:820 ||| ,
while  ||| S:820 E:826 ||| IN
233  ||| S:826 E:830 ||| CD
resulted  ||| S:830 E:839 ||| VBD
negative  ||| S:839 E:848 ||| JJ
for  ||| S:848 E:852 ||| IN
spasmophilia  ||| S:852 E:865 ||| NNS
( ||| S:865 E:866 ||| -LRB-
FM ||| S:866 E:868 ||| NNP
) ||| S:868 E:869 ||| -RRB-
.  ||| S:869 E:871 ||| .
The  ||| S:871 E:875 ||| DT
mean  ||| S:875 E:880 ||| JJ
TP  ||| S:880 E:883 ||| NNP
number  ||| S:883 E:890 ||| NN
resulted  ||| S:890 E:899 ||| VBD
higher  ||| S:899 E:906 ||| JJR
in  ||| S:906 E:909 ||| IN
the  ||| S:909 E:913 ||| DT
FM  ||| S:913 E:916 ||| JJ
group  ||| S:916 E:922 ||| NN
( ||| S:922 E:923 ||| -LRB-
15.33±3.88 ||| S:923 E:933 ||| NNP
)  ||| S:933 E:935 ||| -RRB-
with  ||| S:935 E:940 ||| IN
respect  ||| S:940 E:948 ||| NN
to  ||| S:948 E:951 ||| TO
FM+SP  ||| S:951 E:957 ||| CD
( ||| S:957 E:958 ||| -LRB-
12.88±6.17 ||| S:958 E:968 ||| NNP
,  ||| S:968 E:970 ||| ,
p=0.016 ||| S:970 E:977 ||| CD
) ||| S:977 E:978 ||| -RRB-
,  ||| S:978 E:980 ||| ,
while  ||| S:980 E:986 ||| IN
FIQ  ||| S:986 E:990 ||| NNP
and  ||| S:990 E:994 ||| CC
HAQ  ||| S:994 E:998 ||| NNP
did  ||| S:998 E:1002 ||| VBD
not  ||| S:1002 E:1006 ||| RB
differ  ||| S:1006 E:1013 ||| VB
between  ||| S:1013 E:1021 ||| IN
the  ||| S:1021 E:1025 ||| DT
two  ||| S:1025 E:1029 ||| CD
studied  ||| S:1029 E:1037 ||| CD
groups ||| S:1037 E:1043 ||| NNS
.  ||| S:1043 E:1045 ||| .
FM  ||| S:1045 E:1048 ||| NNP
patients  ||| S:1048 E:1057 ||| NNS
exhibited  ||| S:1057 E:1067 ||| VBP
a  ||| S:1067 E:1069 ||| DT
higher  ||| S:1069 E:1076 ||| JJR
frequency  ||| S:1076 E:1086 ||| NN
of  ||| S:1086 E:1089 ||| IN
psychiatric  ||| S:1089 E:1101 ||| JJ
disorders  ||| S:1101 E:1111 ||| NNS
with  ||| S:1111 E:1116 ||| IN
respect  ||| S:1116 E:1124 ||| NN
to  ||| S:1124 E:1127 ||| TO
FM+SP  ||| S:1127 E:1133 ||| CD
patients  ||| S:1133 E:1142 ||| NNS
( ||| S:1142 E:1143 ||| -LRB-
72 ||| S:1143 E:1145 ||| CD
%  ||| S:1145 E:1147 ||| NN
FM  ||| S:1147 E:1150 ||| NN
vs.  ||| S:1150 E:1154 ||| IN
49 ||| S:1154 E:1156 ||| CD
%  ||| S:1156 E:1158 ||| NN
FM+SP ||| S:1158 E:1163 ||| NN
,  ||| S:1163 E:1165 ||| ,
p  ||| S:1165 E:1166 ||| CD
< ||| S:1166 E:1167 ||| SYM
0.01 ||| S:1167 E:1171 ||| CD
) ||| S:1171 E:1172 ||| -RRB-
.  ||| S:1172 E:1174 ||| .
In  ||| S:1174 E:1177 ||| IN
particular  ||| S:1177 E:1188 ||| JJ
the  ||| S:1188 E:1192 ||| DT
frequency  ||| S:1192 E:1202 ||| NN
of  ||| S:1202 E:1205 ||| IN
depression  ||| S:1205 E:1216 ||| NN
was  ||| S:1216 E:1220 ||| VBD
65.5 ||| S:1220 E:1224 ||| CD
%  ||| S:1224 E:1226 ||| NN
FM  ||| S:1226 E:1229 ||| NN
vs.  ||| S:1229 E:1233 ||| IN
35 ||| S:1233 E:1235 ||| CD
%  ||| S:1235 E:1237 ||| NN
FM+SP  ||| S:1237 E:1243 ||| NNP
( ||| S:1243 E:1244 ||| -LRB-
p  ||| S:1244 E:1245 ||| CD
< ||| S:1245 E:1246 ||| SYM
0.01 ||| S:1246 E:1250 ||| CD
) ||| S:1250 E:1251 ||| -RRB-
.  ||| S:1251 E:1253 ||| .
The  ||| S:1253 E:1257 ||| DT
presence  ||| S:1257 E:1266 ||| NN
of  ||| S:1266 E:1269 ||| IN
spasmophilia  ||| S:1269 E:1282 ||| NN
seems  ||| S:1282 E:1288 ||| VBZ
to  ||| S:1288 E:1291 ||| TO
influence  ||| S:1291 E:1301 ||| VB
psychiatric  ||| S:1301 E:1313 ||| JJ
comorbidity  ||| S:1313 E:1325 ||| NN
which  ||| S:1325 E:1331 ||| WDT
was  ||| S:1331 E:1335 ||| VBD
less  ||| S:1335 E:1340 ||| RBR
prevalent  ||| S:1340 E:1350 ||| JJ
in  ||| S:1350 E:1353 ||| IN
FM+SP  ||| S:1353 E:1359 ||| CD
patients ||| S:1359 E:1367 ||| NNS
.  ||| S:1367 E:1369 ||| .
FM  ||| S:1369 E:1372 ||| NNP
is  ||| S:1372 E:1375 ||| VBZ
indeed  ||| S:1375 E:1382 ||| RB
characterised  ||| S:1382 E:1396 ||| VBN
by  ||| S:1396 E:1399 ||| IN
an  ||| S:1399 E:1402 ||| DT
abnormal  ||| S:1402 E:1411 ||| JJ
sensory  ||| S:1411 E:1419 ||| JJ
processing  ||| S:1419 E:1430 ||| NN
of  ||| S:1430 E:1433 ||| IN
pain  ||| S:1433 E:1438 ||| NN
that  ||| S:1438 E:1443 ||| WDT
seems  ||| S:1443 E:1449 ||| VBZ
to  ||| S:1449 E:1452 ||| TO
result  ||| S:1452 E:1459 ||| VB
from  ||| S:1459 E:1464 ||| IN
a  ||| S:1464 E:1466 ||| DT
combination  ||| S:1466 E:1478 ||| NN
of  ||| S:1478 E:1481 ||| IN
interactions  ||| S:1481 E:1494 ||| NNS
between  ||| S:1494 E:1502 ||| IN
neurotransmitters ||| S:1502 E:1519 ||| NN
,  ||| S:1519 E:1521 ||| ,
stress ||| S:1521 E:1527 ||| NN
,  ||| S:1527 E:1529 ||| ,
hormones  ||| S:1529 E:1538 ||| NNS
and  ||| S:1538 E:1542 ||| CC
the  ||| S:1542 E:1546 ||| DT
nervous  ||| S:1546 E:1554 ||| JJ
system ||| S:1554 E:1560 ||| NN
;  ||| S:1560 E:1562 ||| :
spasmophilia  ||| S:1562 E:1575 ||| NNS
would  ||| S:1575 E:1581 ||| MD
seem  ||| S:1581 E:1586 ||| VB
to  ||| S:1586 E:1589 ||| TO
be  ||| S:1589 E:1592 ||| VB
more  ||| S:1592 E:1597 ||| RBR
linked  ||| S:1597 E:1604 ||| VBN
to  ||| S:1604 E:1607 ||| TO
a  ||| S:1607 E:1609 ||| DT
dysfunction  ||| S:1609 E:1621 ||| NN
at  ||| S:1621 E:1624 ||| IN
the  ||| S:1624 E:1628 ||| DT
neuromuscular  ||| S:1628 E:1642 ||| JJ
level ||| S:1642 E:1647 ||| NN
.  ||| S:1647 E:1649 ||| .
